OXFORD BIOSYSTEMS LIMITED
UNAUDITED FINANCIAL STATEMENTS
FOR THE YEAR ENDED
31 DECEMBER 2025
Company Registration Number: 04159947

OXFORD BIOSYSTEMS LIMITED
UNAUDITED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2025
CONTENTS | PAGES
Company information | 1
Director's report | 2 to 3
Balance sheet | 4 to 5
Notes to the financial statements |  |  |  |  |  | 6 to 12

OXFORD BIOSYSTEMS LIMITED
COMPANY INFORMATION
FOR THE YEAR ENDED 31 DECEMBER 2025
DIRECTOR
Mrs F E Alcock
SECRETARY
The company does not have an appointed secretary
REGISTERED OFFICE
184b Park Drive
Milton Park
Abingdon
Oxon
OX14 4SE
COMPANY REGISTRATION NUMBER
04159947 England and Wales

OXFORD BIOSYSTEMS LIMITED
DIRECTOR'S REPORT
FOR THE YEAR ENDED 31 DECEMBER 2025
The director presents her annual report with the unaudited financial statements of the company for the year ended
31 December 2025.
DIRECTOR
The following director held office during the year:
Mrs F E Alcock
PRINCIPAL ACTIVITY AND BUSINESS REVIEW
The company acts as a distributor providing diagnostic instrumentation and reagents to hospital laboratories, academic institutions and biomedical organisations within the UK and Republic of Ireland. As a distribution company, partnerships with key suppliers using the latest technology and innovative products, are fundamental in ensuring the continued growth of the company in a rapidly evolving market.
During 2025 the company continued the implementation of changes in structure and strategy that were started in 2023 to meet the challenges of being a small privately owned company in our defined market. Business relationships with all our suppliers were maintained and continue to be strengthened through regular communication and collaboration.
During 2025 the company maintained consistent growth in sales and continued to invest in our people, our carbon reduction plan, and in supporting the needs of our customers. The revenue and profitability presented in these financial statements is the result of the ongoing investment in our strategy.
FUTURE PROSPECTS
The company will continue to address new regulatory requirements for the diagnostic industry that are coming into effect globally, and specifically in the UK, during the coming years. This includes the awareness of the effect of climate change and the need for an environmental policy that incorporates an effective carbon reduction plan and social responsibility.
We are committed to acting ethically and with integrity in all our business dealings and relationships, and the company has a zero tolerance approach to modern slavery.
The comprehensive technical and service support for the product portfolio now offered to our strategic market segments will be maintained, and we will continue to provide the excellent customer service that has always been our priority. Our product portfolio is being enhanced by new products incorporating innovation in technology as well as new biomarkers and clinical applications within our defined strategic market segments.
The company is in a stable position with a clear strategy and plans for sustainable growth and continued profitability in 2026. The management team is confident that the company will continue to meet our expectations for the foreseeable future.

OXFORD BIOSYSTEMS LIMITED
DIRECTOR'S REPORT
FOR THE YEAR ENDED 31 DECEMBER 2025
SMALL COMPANY REGIME
This report has been prepared in accordance with the special provisions relating to companies subject to the small companies regime within Part 15 of the Companies Act 2006.
BY ORDER OF THE BOARD
Mrs F E Alcock
Director
Date approved by the board: 6 April 2026

OXFORD BIOSYSTEMS LIMITED
BALANCE SHEET
AS AT 31 DECEMBER 2025
|  |  | Notes |  | 2025 |  |  |  | 2024
|  |  |  |  | £ |  |  |  | £
FIXED ASSETS
Tangible assets | 5 |  |  |  | 97,652 |  |  |  | 95,329
CURRENT ASSETS
Stock | 126,647 |  |  |  | 127,377
Debtors | 6 |  | 286,214 |  |  |  | 318,739
Cash at bank and in hand | 73,643 |  |  |  | 22,778
|  |  |  |  | 486,504 |  |  |  | 468,894
CREDITORS: Amounts falling due within one year | 7 |  | 329,099 |  |  |  | 421,812
NET CURRENT ASSETS | 157,405 |  |  |  | 47,082
TOTAL ASSETS LESS CURRENT LIABILITIES | 255,057 |  |  |  | 142,411
Provisions for liabilities and charges | 16,126 |  |  |  | 11,597
NET ASSETS | 238,931 |  |  |  | 130,814
CAPITAL AND RESERVES
Called up share capital | 1,001 |  |  |  | 1,001
Distributable profit and loss account | 237,930 |  |  |  | 129,813
SHAREHOLDER'S FUNDS | 238,931 |  |  |  | 130,814

OXFORD BIOSYSTEMS LIMITED
BALANCE SHEET
AS AT 31 DECEMBER 2025
These accounts have been prepared and delivered in accordance with the special provisions relating to small companies within Part 15 of the Companies Act 2006 and in accordance with the provisions of FRS 102 Section 1A - small entities.
For the financial year ended 31 December 2025 the company was entitled to exemption from audit under section 477 of the Companies Act 2006.
Members have not required the company to obtain an audit in accordance with section 476 of the Act.
The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of accounts.
As permitted by S444 (5A) of the Companies Act 2006 the directors have not delivered to the Registrar a copy of the company’s Profit and Loss Account.
Signed on behalf of the board
Mrs F E Alcock
Director
Date approved by the board: 6 April 2026

OXFORD BIOSYSTEMS LIMITED
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2025
1 | GENERAL INFORMATION
| Oxford Biosystems Limited is a private company limited by shares and incorporated in England and Wales. Its registered office is:
| 184b Park Drive
| Milton Park
| Abingdon
| Oxon
| OX14 4SE
| The financial statements are presented in Sterling, which is the functional currency of the company.
2 | SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
| Basis of preparation of financial statements
| These financial statements have been prepared in accordance with applicable United Kingdom accounting standards, including Financial Reporting Standard 102 Section 1A smaller entities 'The Financial Reporting Standard applicable in the UK and Republic of Ireland' ('FRS 102') and the Companies Act 2006.
| Revenue recognition

| Turnover is measured at the fair value of consideration received or receivable. It is recognised in respect of the wholesale of pharmaceutical goods and related services as soon as there is a right to consideration and is determined by reference to the value of the work performed. Turnover is stated net of trade discounts and value added tax.
| The company recognises revenue when the amount of revenue can be measured reliably and when it is probable that future economic benefits will flow to the entity.

OXFORD BIOSYSTEMS LIMITED
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2025
2 | SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued…)
| Tangible fixed assets

| Fixed assets are carried at cost less accumulated depreciation and accumulated impairment losses.

| Depreciation has been provided at the following rates so as to write off the cost or valuation of assets less residual value of the assets over their estimated useful lives.
| Plant and machinery | Reducing balance basis at 25% per annum and straight line bases at 10% and 20% per annum
| Fixtures and fittings | Reducing balance basis at 25% per annum
| Computer equipment | Reducing balance basis at 25% per annum
| Leasehold improvements | Reducing balance basis at 10% per annum
| On disposal, the difference between the net disposal proceeds and the carrying amount of the item sold is recognised in the profit and loss account, and included within administrative expenses.
| Financial Instruments
| A financial asset or financial liability is recognised only when the entity becomes a party to the contractual provisions of the instrument.
| The company only enters into basic financial instruments transactions that result in the recognition of financial assets and liabilities like trade and other accounts receivable and payable, loans from banks and other third parties, loans to related parties and investments in non-puttable ordinary shares.
| Where investments in non-derivative financial instruments are publicly traded, or their fair value can otherwise be measured reliably, the investment is subsequently measured at fair value through the profit and loss account.
| Basic financial assets and financial liabilities are initially recognised at transaction price and measured at amortised cost using the effective interest method unless the arrangement constitutes a financing transaction. They are subsequently carried at their amortised cost using the effective interest rate method, less any provision for impairment. If the effect of the time value of money is immaterial, they are measured at cost less impairment.
| Basic financial assets and liabilities which are measured at cost or amortised cost are reviewed for objective impairment at each balance sheet date. If there is objective evidence of impairment, an impairment loss is recognised in the profit and loss account immediately.

| Any reversals of impairment are recognised in the profit or loss immediately, to the extent that the reversal does not result in a carrying amount of the financial asset or liability which exceeds what the carrying amount would have been had the impairment loss not previously been recognised.

| Financing transactions are measured at the present value of the future receipts discounted at a market rate of interest. They are subsequently measured at amortised costs using the effective interest method. Discounting is omitted where the effect of discounting is immaterial.

OXFORD BIOSYSTEMS LIMITED
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2025
2 | SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued…)
| Impairment of non-financial assets

| At each reporting date non-financial assets not carried at fair value, like goodwill and plant, property and equipment, are reviewed to determine whether there is an indication that an asset may be impaired. If there is an indication of possible impairment, the recoverable amount of any asset or group of related assets (which is the higher of value in use and the fair value less cost to sell) is estimated and compared with its carrying amount. If the recoverable amount is lower, the carrying amount of the asset is reduced to its recoverable amount and an impairment loss is recognised immediately in the profit and loss account.
| Stocks are assessed for impairment at each reporting date. The carrying amount of each item of stock, or group of similar items, is compared with its selling price less cost to complete and sell. If an item of stock, or group of similar items, is impaired its carrying amount is reduced to selling price less costs to complete and sell, and an impairment loss is recognised immediately in the profit and loss account.
| If an impairment loss is subsequently reversed, the carrying amount of the asset, or group of related assets, is increased to the revised estimate of its recoverable amount, but not to exceed the amount that would have been determined had no impairment loss been recognised for the asset, or group of related assets, in prior periods. A reversal of an impairment loss is recognised immediately in the profit and loss account.

| Stock

| Stock has been valued at the lower of cost and estimated selling price less cost to complete and sell, after making due allowance for obsolete and slow-moving items. Cost comprises the cost of goods purchased valued on a first in first out basis.
| The carrying amount of stock sold is recognised as an expense in the period in which the related revenue is recognised.

| Debtors

| Short term debtors are measured at transaction price, less any impairment.

| Creditors
| Short term trade creditors are measured at the transaction price. Other financial liabilities, including bank loans, are measured initially at fair value, net of transaction costs, and subsequently at amortised cost.

OXFORD BIOSYSTEMS LIMITED
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2025
2 | SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued…)
| Leases
| Leases are classified as finance leases when they transfer substantially all the risks and rewards of ownership of the leased assets to the company. Other leases that do not transfer substantially all the risks and rewards of ownership of the leased assets to the company are classified as operating leases.

| Assets held under finance leases are recognised in accordance with the company's policy for tangible fixed assets. The corresponding obligations to lessors under finance leases are treated in the balance sheet as a liability. The assets and liabilities under finance leases are recognised at amounts equal to the fair value of the assets, or if lower, the present value of minimum lease payments, determined at the inception of the lease.
| Minimum lease payments are apportioned between finance charges and the reduction in the outstanding liabilities using the effective interest method. The finance charge is allocated to each period during the lease so as to produce a constant rate of interest on the remaining balance of the liabilities. Finance charges are recognised in the profit and loss account.

| Payments applicable to operating leases are charged against profit on a straight line basis over the lease term.
| Taxation
| Taxation expense represents the aggregate amount of current tax and deferred tax recognised in the reporting period.
| A current tax liability is recognised for the tax payable on the taxable profit of the current and past periods based on current tax rates and laws. A current tax asset is recognised in respect of a tax loss that can be carried back to recover tax paid in a previous period.

| Deferred tax is recognised in respect of all timing differences between the recognition of income and expenses in the financial statements and their inclusion in tax assessments. Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other taxable profits.
| Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the reporting date and that are expected to apply to the reversal of the timing difference.

| Current and deferred tax assets and liabilities are not discounted.
| Foreign currencies

| Transactions in foreign currencies are initially recognised at the rate of exchange ruling at the date of the transaction.
| Monetary assets and liabilities denominated in foreign currencies at the balance sheet date are translated at the rate of exchange prevailing at that date. Non-monetary items that are measured at historical cost are translated at the rate ruling at the date of the transaction. Exchange differences are taken into account in arriving at the operating profit or loss.

OXFORD BIOSYSTEMS LIMITED
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2025

2 | SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued…)
| Pensions
| The company operates a defined contribution pension scheme. The amount charged to the profit and loss account in respect of pension costs and other post-retirement benefits is the amount payable in the year. Differences between contributions payable and contributions actually paid in the year are shown as either accruals or prepayments in the balance sheet.
3 | CRITICAL ACCOUNTING ESTIMATES AND JUDGEMENTS

| No significant accounting estimates and judgements have had to be made by the director in preparing these financial statements.

4 | EMPLOYEES
| The average number of persons employed by the company (including the director) during the year was:
|  |  |  |  |  |  |  |  | 2025 |  | 2024
| Average number of employees | 14 |  | 14

OXFORD BIOSYSTEMS LIMITED
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2025
5 | TANGIBLE ASSETS
|  |  | Plant and machinery |  | Fixtures and fittings |  | Computer equipment | Leasehold improvements | Total
|  |  | £ |  | £ |  | £ |  | £ |  | £
| Cost
| At 1 January 2025 | 129,876 |  | 39,444 |  | 65,772 |  | 43,444 |  | 278,536
| Additions | 12,575 |  | 3,017 |  | 7,997 |  | - |  | 23,589
| Disposals | (4,273) |  | - |  | - |  | - |  | (4,273)
| At 31 December 2025 | 138,178 |  | 42,461 |  | 73,769 |  | 43,444 |  | 297,852
| Accumulated depreciation
| At 1 January 2025 | 83,256 |  | 31,714 |  | 55,406 |  | 12,831 |  | 183,207
| Charge for year | 10,627 |  | 2,337 |  | 3,626 |  | 3,061 |  | 19,651
| Disposals | (2,658) |  | - |  | - |  | - |  | (2,658)
| At 31 December 2025 | 91,225 |  | 34,051 |  | 59,032 |  | 15,892 |  | 200,200
| Net book value
| At 1 January 2025 | 46,620 |  | 7,730 |  | 10,366 |  | 30,613 |  | 95,329
| At 31 December 2025 | 46,953 |  | 8,410 |  | 14,737 |  | 27,552 |  | 97,652
6 | DEBTORS
|  |  |  |  |  |  |  |  | 2025 |  | 2024
|  |  |  |  |  |  |  |  | £ |  | £
| Trade debtors | 247,936 |  | 230,689
| Amounts owed from group undertakings | 2,820 |  | -
| Prepayments and accrued income | 24,444 |  | 68,106
| Other debtors | 11,014 |  | 19,944
|  |  |  |  |  |  |  |  | 286,214 |  | 318,739
7 | CREDITORS: Amounts falling due within one year
|  |  |  |  |  |  |  |  | 2025 |  | 2024
|  |  |  |  |  |  |  |  | £ |  | £
| Trade creditors | 130,497 |  | 191,413
| Taxation and social security | 71,345 |  | 78,523
| Accruals and deferred income | 119,923 |  | 144,783
| Other creditors | 7,334 |  | 7,093
|  |  |  |  |  |  |  |  | 329,099 |  | 421,812

OXFORD BIOSYSTEMS LIMITED
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2025
8 | CONTINGENCIES AND COMMITMENTS
| Other Commitments
| Amounts falling due under operating leases: | 2025 |  | 2024
|  |  |  |  |  |  |  |  | £ |  | £
| In less than one year | 88,000 |  | 88,000
| In more than one but less than five years | 29,333 |  | 117,333
|  |  |  |  |  |  |  |  | 117,333 |  | 205,333
9 | RELATED PARTY TRANSACTIONS
| The company has claimed exemptions from reporting disclosure of related party transactions with the following wholly owned group members:
| Featherleaf Limited | Immediate parent

Oxford Biosystems Limited 04159947 false 2025-01-01 2025-12-31 2025-12-31 VT Final Accounts (tagged by user) July 2024 true true No description of principal activity 04159947 2024-01-01 2024-12-31 04159947 core:WithinOneYear 2024-12-31 04159947 core:ShareCapital 2024-12-31 04159947 core:RetainedEarningsAccumulatedLosses 2024-12-31 04159947 core:CurrentFinancialInstruments 2024-12-31 04159947 core:WithinOneYear core:PlantEquipmentOtherAssetsUnderOperatingLeases 2024-12-31 04159947 core:BetweenOneFiveYears core:PlantEquipmentOtherAssetsUnderOperatingLeases 2024-12-31 04159947 2025-01-01 2025-12-31 04159947 bus:PrivateLimitedCompanyLtd 2025-01-01 2025-12-31 04159947 bus:AuditExempt-NoAccountantsReport 2025-01-01 2025-12-31 04159947 bus:Director1 2025-01-01 2025-12-31 04159947 bus:RegisteredOffice 2025-01-01 2025-12-31 04159947 core:FurnitureFittings 2025-01-01 2025-12-31 04159947 core:ComputerEquipment 2025-01-01 2025-12-31 04159947 core:LeaseholdImprovements 2025-01-01 2025-12-31 04159947 core:PlantMachinery 2025-01-01 2025-12-31 04159947 core:ImmediateParent 2025-01-01 2025-12-31 04159947 bus:FRS102 2025-01-01 2025-12-31 04159947 bus:FilletedAccounts 2025-01-01 2025-12-31 04159947 2025-12-31 04159947 core:WithinOneYear 2025-12-31 04159947 core:ShareCapital 2025-12-31 04159947 core:RetainedEarningsAccumulatedLosses 2025-12-31 04159947 core:PlantMachinery 2025-12-31 04159947 core:FurnitureFittings 2025-12-31 04159947 core:ComputerEquipment 2025-12-31 04159947 core:LeaseholdImprovements 2025-12-31 04159947 core:CurrentFinancialInstruments 2025-12-31 04159947 core:WithinOneYear core:PlantEquipmentOtherAssetsUnderOperatingLeases 2025-12-31 04159947 core:BetweenOneFiveYears core:PlantEquipmentOtherAssetsUnderOperatingLeases 2025-12-31 04159947 2024-12-31 04159947 core:PlantMachinery 2024-12-31 04159947 core:FurnitureFittings 2024-12-31 04159947 core:ComputerEquipment 2024-12-31 04159947 core:LeaseholdImprovements 2024-12-31 iso4217:GBP xbrli:pure